MedTrace Logo

Effect of Moringa Oleifera on Metformin Plasma Level in Type 2 Diabetes Mellitus Patients

NCT03189407 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-06-16

No results posted yet for this study

Summary

Type 2 diabetes mellitus (T2DM) patients from our previous survey tend to co-administer various herbs with their oral hypoglycemic agents (OHA). Some of these herbs are known to possess antidiabetic activities. One of such is Moringa oleifera leaves.

The present study evaluated the effects of seven days, twice-daily administration of hot water infusion of dried Moringa oleifera leaves on the steady state plasma concentrations of Metformin, one of the most widely used OHAs using T2DM patients who have been on Metformin for a period of not less than three months. The included patients had also been on Moringa supplementation but had terminated the use of Moringa at least a month to the start of the study.

Patients who had other comorbidities such as heart diseases, renal or hepatic impairments were excluded from the study. The patients were recruited from Endocriniology clinic of the Obafemi Awolowo University Teaching Hospitals complex, a tertiary hospital from southwest Nigeria.

Each patient served as his/her control.

Conditions

Interventions

DIETARY_SUPPLEMENT

Moringa oleifera tea

Sponsors & Collaborators

  • Titilayo O Fakeye

    lead OTHER

Principal Investigators

  • Toyin Famurewa, B.Pharm;MSc · Obafemi Awolowo University Hospitals Complex, Ile-Ife, Nigeria

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
49 Years
Max Age
77 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2016-04-30
Completion
2016-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03189407 on ClinicalTrials.gov